



Medical Policy Name	Transcranial Magnetic Stimulation for the Treatment of Major Depression for Florida Blue
Medical Policy Number	20.5.008
Issued By	Chief Medical Officer
Approved By	Medical Directors, Provider Advisory Committee, Corporate Quality Improvement Committee
Original Effective Date	02/2025

Applies To: 01/01/2026 to 12-31-2026

Description of Treatment

Transcranial magnetic stimulation (TMS) is a treatment technique that uses a magnetic field to influence brain activity. It is noninvasive and can help when other treatment approaches are not effective. The side effects are usually mild and temporary.

When Services May Be Eligible for Coverage

Coverage for eligible treatments or procedures may be provided only if:

- Benefits are available in the member's contract/certificate, and
- Medical necessity criteria and guidelines are met.

Criteria

A. Expectations of Care Delivery

1. Training and Requirements

- a. Lucet will register any clinics or practitioners via documentation of certification, prior to allowing use of this benefit.
- b. Psychiatrist
 - i. Board-certified psychiatrist with training in the use of TMS for Major Depression.
 - ii. Required to personally perform first TMS treatment (including cortical mapping, motor threshold determination, delivery, and management) and re-determination of the Motor Threshold (MT).
 - iii. Subsequent TMS treatment may be administered by a psychiatrist.
- c. TMS Technician
 - i. Required to have certification in administering TMS.
 - ii. Subsequent TMS treatment may be administered by a technician.

2. TMS administered with an FDA-approved or cleared device.

3. One (1) treatment session per day is given for five (5) consecutive days per week for six (6) consecutive weeks. Immediately following the six (6) (week treatment period, the treatment frequency is tapered, as follows:
 - a. Week One (after six-week initial treatment): 3 treatment sessions
 - b. Week Two (after six-week initial treatment): 2 treatment sessions
 - c. Week Three (after six-week initial treatment): 1 treatment session
4. Standardized depression rating scales (Table 1) will be administered during TMS treatment to monitor progress at a minimal frequency of an initial pre-treatment test which is to occur prior to the six (6) week initial treatment period, followed by testing every two (2) weeks during the six (6) week treatment period and a final test at the last treatment visit. If the rating scales document a lack of meaningful change or worsening of symptom intensity, review by a physician advisor may be indicated.
 - a. For consistency, one (1) rating scale should be chosen and administered during the entire treatment course.

Table 1 - Clinically Accepted Depression Rating Scales include but are not limited to:

Name	Number of items	Minimum score for initial authorization
Beck Depression Inventory (BDI)	21	>29
Inventory of Depressive Symptomatology Clinician-rated (IDS-C)	30	>36
Quick Inventory of Depressive Symptomatology Self-reported (QIDS-SR)	16	>15
Montgomery-Asberg Depression Rating Scale (MADRS)	10	>34
Patient Health Questionnaire (PHQ9)	9	>19

B. Initial Authorization Request

1. TMS meets the definition of medical necessity for a treatment resistant major depressive disorder when **ALL of the following criteria (sections a-c) have been met.**
 - a. Confirmed diagnosis of severe Major Depressive Disorder WITHOUT Psychosis (International Classification of Disease: ICD-9 codes 296.2x and 296.3X, and ICD -10 codes F32.x and F33.x).
 - i. Severity documented by one (1) clinically accepted depression rating scale from Table 1.
 - b. The request is for a member between the ages of 15 and 70.
 - c. The member has any **one of the following:**

- i. Failure of two (2) trials of psychopharmacologic agents approved by the FDA for treating Major Depressive Disorder. These must include:
 - 1) Medicine trials from at least two (2) different antidepressant classes (for example SSRI, SNRI, TCA, MAI-O, etc.)
- ii. Inability to tolerate a therapeutic dose of medications as evidenced by two (2) trials of psychopharmacologic agents from at least two (2) different antidepressant classes with documented distinct intolerable side effects.
- iii. The member's condition meets Lucet Health medical policy for Electroconvulsive Therapy (ECT), and both of the following are met:
 - 1) There is documentation that the member has been evaluated for ECT, and clinical circumstances prevent the use of ECT.
 - 2) ECT outcome would not be overall superior to TMS (e.g., in cases with psychosis, acute suicidal risk, catatonia, or life-threatening dysfunction in basic life needs. In these conditions, TMS should not be utilized.)

C. Retreatment Requests for TMS

1. **Must meet both (a) and (b):**

- a. Meets all requirements for initial TMS treatment (above)
- b. Repeat acute treatment for relapse of depressive symptoms is considered medically necessary when both (a) and (b) are met:
 - i. There is documentation submitted that the member responded to prior treatments, specifically with a 50% or greater improvement in a standard rating scale for depressive symptoms (Table 1).
 - ii. A minimum of ninety (90) days has elapsed since the termination of the prior TMS treatment course.

D. Authorization if Determined to be Medically Necessary

1. Initial authorization:

- a. One (1) unit of 90867, 36 units of 90868, and one (1) unit of 90869.
- b. Requests for additional units of 90869 should be submitted with detailed clinical rationale.

2. Retreatment Requests

- a. 36 units of 90868

E. Limitations of Coverage - The use of TMS with any of the following is considered not appropriate or medically necessary:

1. There is evidence of:

- a. Actively abusing substances (Urine Drug Screen (UDS) confirmation may be required).

- b. Active psychotic symptoms.
 - c. Acute suicidal risk
 - d. Catatonia
 - e. Life-threatening dysfunction in basic life needs
 - f. Active neurologic disorder, including but not limited to encephalopathy, dementia from any cause, Parkinson's Disease, post-stroke syndromes, increased intracranial pressure or bleeding, cerebral aneurysm, A-V malformations, CSF shunts, implants in the CNS or head/neck, etc.
- 2. The request is for treatment of psychiatric diagnoses found in the DSM other than Treatment Resistant Depression.
 - 3. The request is for treatment of OCD.
 - 4. The member has non-removable metallic objects or implants in his/her head or neck regions.
 - 5. The request is for Maintenance TMS Treatment.
 - 6. The request is for Intermittent Theta Burst Stimulation (iTBS).
 - 7. The request is for Magnetic Seizure Therapy (MST), which is using TMS to stimulate the induction of seizures, has been tried as an alternative to the electrical induction of seizures in electroconvulsive therapy (ECT).
 - 8. The request is for Navigated Transcranial Magnetic Stimulation (nTMS) which uses a diagnostic tool to stimulate functional cortical areas at precise anatomical locations to induce measurable responses. This technology is being investigated to map functionally essential motor areas for diagnostic purposes and for treatment planning.

Summary of Evidence

For major depressive disorder, two clinical practice guidelines (CPG) (Walter et al., 2023; McQuaid et al., 2022) recommend psychotherapy and/or pharmacotherapy as first-line treatment interventions for all age groups.

One CPG (McQuaid et al., 2022), for adult patients who have demonstrated partial or no response to two or more adequate pharmacologic treatment trials (sufficient length and adherence), suggested offering repetitive transcranial magnetic stimulation (rTMS) for treatment. The CPG also indicated that there is insufficient evidence to recommend for or against theta-burst stimulation for the treatment of MDD.

Another study (Dalhuisen et al., 2024) found that rTMS was more effective than pharmacological treatment in patients with moderately treatment-resistant depression. Furthermore, greater reductions in symptoms of anxiety and anhedonia were observed after treatment with rTMS, which supports ongoing research in this area. The authors concluded that rTMS should be considered as a viable treatment option at an early stage

of the treatment algorithm and may be more effective than antidepressant medication switch or augmentation.

Repetitive transcranial magnetic stimulation (TMS) is established as effective and FDA-approved for individuals with TRD (Treatment Resistant Depression), with accelerated theta-burst TMS also recently showing efficacy (McIntyre et al., 2023).

Stanford neuromodulation therapy (SNT, previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT), a high-dose iTBS protocol with functional-connectivity-guided targeting (navigated TMS), was more effective than sham stimulation for treatment-resistant depression. This study only had 29 participants who completed the study, limiting conclusions that can be drawn from it. Further trials are needed to determine SNT's durability and to compare it with other treatments (Cole et al., 2022). Whether or not accelerated TBS is equivalent to traditional rTMS is a topic of intense interest. While some studies have shown it to be non-inferior, the most recent investigation by Wada (2025) failed to establish that TBS is non-inferior to rTMS.

Regarding durability of the SNT iTBS, a 2025 study by Geoly showed that most remitters and responders relapsed into depression after 12 weeks. The authors suggested that additional treatments or re-treatment might be necessary. This suggests that the purported time advantage of accelerated treatment may not be available to many members, who might still have to have more treatments or other kinds of treatment after accelerated TBS.

Deep TMS is a technique that penetrates deeper into cortical brain tissue. There are few recent high-quality articles on this method. One 2023 article (Tendler et al., 2023) was a naturalistic study without a control group. Also, in this study, only 67% of participants were severely depressed.

In a 2023 post-marketing study of maintenance TMS (d'Andrea et al., 2023), it was noted that the peak of recovery was often up to 5 months after treatment was completed. Some benefits of treatment did not appear until several months after acute treatment. 14 studies were included, none done in the past 4 years. Only 2 were of TMS that started after acute treatment. There was no agreed upon protocol.

In a 2023 review of TMS for Bipolar Disorder (Mutz, 2023), the author noted that there are few sham-controlled studies of TMS in Bipolar Disorder. Of the main three, one showed effect greater than sham in 2 weeks but not at 4 weeks. Another study of 49 patients did not separate from sham TMS. Another using intermittent theta-burst stimulation (iTBS) did not separate from sham. Most of the positive evidence for TMS efficacy in Bipolar Affective Disorder are case reports and uncontrolled studies. The author noted that there are few sham-controlled studies of TMS in Bipolar Disorder. Of the main three, one showed effect greater than sham in 2 weeks but not at 4 weeks.

Another study of 49 patients did not separate from sham TMS. Another using intermittent theta-burst stimulation (iTBS) did not separate from sham.

Shamabadi et al. (2023) reviewed eleven studies of Bipolar Depression (BD) and response to TMS treatment when combined with neuroimaging modalities (5 navigated TMS methods). The studies suggested that nTMS may have benefits. This study reviewed significant clinical implications of neuroimaging modalities for prognosis, treatment planning, and patient outcomes in patients with bipolar depression who received TMS. Due to limitations, rTMS in BD research needs to be further studied and results replicated.

A pilot study of 31 subjects published in 2024 (Aaronson, et al.) showed positive results for conventional TMS in Bipolar Depression, suggesting that more research may be indicated.

Lorentzen et al. (2022) synthesized literature in a systematic review and quantitative meta-analysis of double-blind randomized controlled trials of TMS in patients with schizophrenia. 57 studies with a total of 2633 participants that were included in the meta-analysis. The author concluded that TMS appears to be an efficacious treatment option for patients with schizophrenia suffering from negative symptoms, but the optimal TMS parameters are yet to be established. There was, however, substantial heterogeneity and high risk of bias among the included studies.

Meta-analysis of updated evidence (Gay et al., 2022) to assess overall rTMS efficacy on craving, differential effects between addiction types clustered into three groups (depressant (alcohol, cannabis, opiate), stimulant (nicotine, cocaine, methamphetamine), and behavioral addiction (gambling, eating disorder)), and stimulation settings. Studies on substance use, gambling, and eating disorders are included, with unrestricted stimulation settings. A total of 34 eligible studies were identified. Because of highly significant heterogeneity in primary results, a sensitivity analysis was performed on a remaining sample of 26 studies (30 units of analysis). Analyses performed using random effects model revealed a small effect size favoring active rTMS over shamTMS stimulation in the reduction in craving. The authors found a significant difference between addiction types, with a persistent small effect only for stimulant and behavioral groups. Efficacy of rTMS on craving in stimulant and behavioral addiction was highlighted, but recommendations on optimal stimulation settings and its clinical application await further research.

In March 2024, the FDA cleared three TMS devices for adjunctive treatment for major depressive disorder in adolescents aged 15 and up (Croarkin et al., 2024). These are the NeuroStar Advanced Therapy system, the Magstim Horizon Inspire and 3.0 systems, and the Apollo TMS Therapy Devices. The clearance was a marketing clearance, meaning providers can be reimbursed for administering TMS to adolescents. . This decision was made based on a research poster describing a naturalistic study of 1169 subjects who

received TMS for major depressive disorder. Initial PHQ-9 scores were as low as 10 and the average age was 19.2 years old. TMS treatment resulted in improvement in both depressive symptoms and anxiety in both adolescents and young adults. As a naturalistic study, there was no control group. The authors concluded that TMS treatment resulted in improvement in both depressive symptoms and anxiety in both adolescents and young adults. An article associated with the study is in press (Croarkin et al., 2025).

In a 2022 systematic review of TMS in children and adolescents (Sigrist et al., 2022), the review notes: “To date, two randomized controlled trials on TMS in adolescent depression have been studied, and the only large-scale randomized trial suggests TMS is not more effective than sham stimulation.” This refers to the Croarkin 2021 study, where in adolescents both TMS and sham groups responded with improvement. Another review (Qiu et al., 2023) noted, “Repetitive transcranial magnetic stimulation (rTMS) benefits adults with depression while its efficacy and safety in children and adolescents with major depressive disorder (MDD) remain unclear.” It also noted most studies did not have a sham control group.

One CPG for children and adolescents (Walter et al., 2023) did not recommend TMS but noted that it was one area for additional treatment research. As of 2025, the American Academy of Child and Adolescent Psychiatry continues to take the position that the efficacy and safety of TMS in members under the age of 18 is not established.

Several articles have come out regarding use of TMS in a geriatric population.

- In a 2022 retrospective review of geriatric depression (Cappon et al., 2022), the study subjects included subjects as young as 50. Studies had varying results and within studies results were heterogeneous. The RCT's done were not large studies.
- A 2022 study (Blumberger, et al., 2022) compared bilateral theta-burst stimulation (TBS) to conventional TMS and found it to be non-inferior. There was more pain with TBS. The average age was 67 years old. Subjects were rated using the Montgomery-Asberg Depression Rating Scale. In the TMS group, average decrease in depression scores was 32%. In the TBS group, the decrease was 38.5%. 35% of this group went into remission. However, subjects before treatment had average scores in the mild to moderate range on the MADRS, and had failed only one antidepressant medication. This limits the ability to generalize the results to clinical populations.
- In another retrospective analysis (Almheiri et al., 2023), the oldest subject was 71, so it does not inform of any potential change to our current policy limit of age 70. The mean age was 66. It also noted that the usual way of doing rTMS, Left DLPFC treatment, had no effect, only bilateral TMS did. The author speculated that more effective protocols for geriatric patients might be developed in the future.

Recently the FDA cleared the Brainsway TMS device to treat older members, ages 70-86. However, the current literature does not adequately support raising the policy age limit of age 70 for TMS authorization.

The Brainsway device is said to be deep transcranial magnetic stimulation (dTMS) safe and effective as a treatment alternative for OCD and recently received regulatory approvals (Roth et al., 2020). Data from one double-blind multicenter dTMS study found efficacy of this novel treatment in OCD patient who previously failed to respond to multiple medications and CBT. Limitations of this analysis included small sample size and the lack of controlled monitoring of prior pharmacological and psychotherapy treatments.

In real-world clinical practice, the majority of OCD patients benefitted from dTMS, and the onset of improvement usually occurs within 20 sessions (Roth et al., 2021). Extending the treatment course beyond 29 sessions results in continued reduction of OCD symptoms, raising the prospect of value for extended treatment protocols in non-responders.

Exceptions

Exceptions to this medical policy must be approved by Lucet Chief Medical Officer or their designee.

References

1. Aaronson ST, Goldwaser EL, Croarkin PE, Geske JR, LeMahieu A, Sklar JH, Kung S. A Pilot Study of High-Frequency Transcranial Magnetic Stimulation for Bipolar Depression. *J Clin Psychiatry*. 2024 May 20;85(2):23m15056. doi: [10.4088/JCP.23m15056](https://doi.org/10.4088/JCP.23m15056). PMID: 38780536.
2. Almheiri E, Alhelali A, Abdelnaim MA, Weber FC, Langguth B, Schecklmann M, Hebel T. Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Depression in the Elderly: A Retrospective Natural Analysis. *J Clin Med*. 2023 Jul 18;12(14):4748. doi: [10.3390/jcm12144748](https://doi.org/10.3390/jcm12144748). PMID: 37510863; PMCID: PMC10381588.
3. Blumberger DM, Mulsant BH, Thorpe KE, et al. Effectiveness of Standard Sequential Bilateral Repetitive Transcranial Magnetic Stimulation vs Bilateral Theta Burst Stimulation in Older Adults With Depression: The FOUR-D Randomized Noninferiority Clinical Trial. *JAMA Psychiatry*. 2022;79(11):1065–1073. doi:[10.1001/jamapsychiatry.2022.2862](https://doi.org/10.1001/jamapsychiatry.2022.2862)
4. Cappon D, den Boer T, Jordan C, Yu W, Metzger E, Pascual-Leone A. Transcranial magnetic stimulation (TMS) for geriatric depression. *Ageing Res*

Rev. 2022 Feb; 74:101531. doi: [10.1016/j.arr.2021.101531](https://doi.org/10.1016/j.arr.2021.101531). Epub 2021 Nov 25.
PMID: 34839043; PMCID: PMC8996329.

5. Cole, E. J., Phillips, A. L., Bentzley, B. S., Stimpson, K. H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., Brown, R., Choi, E., King, S., Pankow, H., Bishop, J. H., Azeez, A., Coetzee, J., Rapier, R., Odenwald, N., Carreon, D., Williams, N. R. (2022). Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. *The American journal of psychiatry*, 179(2), 132–141. <https://doi.org/10.1176/appi.ajp.2021.20101429>
6. Croarkin PE, Elmaadawi AZ, Aaronson ST, Schrodtt GR Jr, Holbert RC, Verdoliva S, Heart KL, Demitrack MA, Strawn JR. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. *Neuropsychopharmacology*. 2021 Jan;46(2):462-469. doi: 10.1038/s41386-020-00829-y. Epub 2020 Sep 12. PMID: 32919400; PMCID: PMC7852515. <https://pubmed.ncbi.nlm.nih.gov/32919400/>
8. Croarkin, Paul E.; Aaronson, Scott T.; Carpenter, Linda L.; Hutton, Todd M.; Pages, Kenneth P.; Sackeim, Harold A.; et al. A Naturalistic Study of Transcranial Magnetic Stimulation Treatment in Adolescents and Young Adults With Depression and Anxiety. *Journal of the American Academy of Child & Adolescent Psychiatry*, Volume 63, Issue 10, S306, 2024. [https://www.jaacap.org/article/S0890-8567\(24\)01827-6/fulltext](https://www.jaacap.org/article/S0890-8567(24)01827-6/fulltext)
9. Croarkin, P. E., Aaronson, S. T., Carpenter, L. L., Hutton, T. M., Pages, K., Chen, B., & Sackeim, H. A. (2025). The Effectiveness of Transcranial Magnetic Stimulation in Adolescents and Young Adults With Major Depressive Disorder. *JAACAP Open/In Press*. [https://www.jaacapopen.org/article/S2949-7329\(25\)00070-5/fulltext](https://www.jaacapopen.org/article/S2949-7329(25)00070-5/fulltext)
10. Dalhuisen I, van Oostrom I, Spijker J, Wijnen B, van Exel E, van Mierlo H, de Waardt D, Arns M, Tendolkar I, van Eijndhoven P. rTMS as a Next Step in Antidepressant Nonresponders: A Randomized Comparison With Current Antidepressant Treatment Approaches. *Am J Psychiatry*. 2024 Aug 7:appiajp20230556. doi: [10.1176/appi.ajp.20230556](https://doi.org/10.1176/appi.ajp.20230556). Epub ahead of print. PMID: 39108161.
11. D'Andrea, G.; Mancusi, G.; Santovito, M.C.; Marrangone, C.; Martino, F.; Santorelli, M.; Miuli, A.; Di Carlo, F.; Signorelli, M.S.; Clerici, M.; Pettorruso M, Martinotti G. Investigating the Role of Maintenance TMS Protocols for Major Depression: Systematic Review and Future Perspectives for Personalized Interventions. *J. Pers. Med.* 2023, 13, 697. <https://www.mdpi.com/2075-4426/13/4/697>. Academic Editor: Piotr Galeck

12. Gay A, Cabe J, De Chazeron I, Lambert C, Defour M, Bhoowabul V, Charpeaud T, Tremey A, Llorca PM, Pereira B, Brousse G. Repetitive Transcranial Magnetic Stimulation (rTMS) as a Promising Treatment for Craving in Stimulant Drugs and Behavioral Addiction: A Meta-Analysis. *J Clin Med*. 2022 Jan 26;11(3):624. doi: [10.3390/jcm11030624](https://doi.org/10.3390/jcm11030624). PMID: 35160085; PMCID: PMC8836499.
13. Geoly AD, Stimpson KH, Espil FM, Bentzley BS, Williams NR. Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT) in treatment-resistant depression. *Brain Stimul*. 2025 May-Jun;18(3):875-881. doi: 10.1016/j.brs.2025.04.006. Epub 2025 Apr 8. PMID: 40209894. [https://www.brainstimjrnl.com/article/S1935-861X\(25\)00196-2/fulltext](https://www.brainstimjrnl.com/article/S1935-861X(25)00196-2/fulltext)
14. Lorentzen R, Nguyen TD, McGirr A, Hieronymus F, Østergaard SD. The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis. *Schizophrenia (Heidelb)*. 2022 Apr 9;8(1):35. doi: [10.1038/s41537-022-00248-6](https://doi.org/10.1038/s41537-022-00248-6). PMID: 35853882; PMCID: PMC9261093.
15. McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, Nierenberg AA, Rosenblat JD, Sanacora G, Schatzberg AF, Shelton R, Stahl SM, Trivedi MH, Vieta E, Vinberg M, Williams N, Young AH, Maj M. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. *World Psychiatry*. 2023 Oct;22(3):394-412. doi: [10.1002/wps.21120](https://doi.org/10.1002/wps.21120). PMID: 37713549; PMCID: PMC10503923.
16. McQuaid, J. R., Buelt, A., Capaldi, V., Fuller, M., Issa, F., Lang, A. E., & Williams, S. (2022). The management of major depressive disorder: synopsis of the 2022 US Department of Veterans Affairs and US Department of Defense clinical practice guideline. *Annals of internal medicine*, 175(10), 1440-1451. <https://doi.org/10.7326/M22-160>.
17. Mutz J. Brain stimulation treatment for bipolar disorder. *Bipolar Disord*. 2023 Feb;25(1):9-24. doi: [10.1111/bdi.13283](https://doi.org/10.1111/bdi.13283). Epub 2022 Dec 21. PMID: 36515461; PMCID: PMC10210071.
18. Qiu, H., Liang, K., Lu, L., Gao, Y., Li, H., Hu, X., Xing, H., Huang, X., & Gong, Q. (2023). Efficacy and safety of repetitive transcranial magnetic stimulation in children and adolescents with depression: A systematic review and preliminary meta-analysis. *Journal of affective disorders*, 320, 305–312. <https://doi.org/10.1016/j.jad.2022.09.060>

19. Roth, Y., Barnea-Ygael, N., Carmi, L., Storch, E. A., Tendler, A., & Zangen, A. (2020). Deep transcranial magnetic stimulation for obsessive-compulsive disorder is efficacious even in patients who failed multiple medications and CBT. *Psychiatry research*, 290, 113179. <https://doi.org/10.1016/j.psychres.2020.113179>
20. Roth, Y., Tendler, A., Arikan, M. K., Vidrine, R., Kent, D., Muir, O., MacMillan, C., Casuto, L., Grammer, G., Sauve, W., Tolin, K., Harvey, S., Borst, M., Rifkin, R., Sheth, M., Cornejo, B., Rodriguez, R., Shakir, S., Porter, T., Kim, D., Zangen, A. (2021). Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites. *Journal of psychiatric research*, 137, 667– 672. <https://doi.org/10.1016/j.jpsychires.2020.11.009>
21. Shamabadi, A., Karimi, H., Cattarinussi, G., Moghaddam, H. S., Akhondzadeh, S., Sambataro, F., Schiena, G., & Delvecchio, G. (2023). Neuroimaging Correlates of Treatment Response to Transcranial Magnetic Stimulation in Bipolar Depression: A Systematic Review. *Brain sciences*, 13(5), 801. <https://doi.org/10.3390/brainsci13050801>
22. Sigrist C, Vöckel J, MacMaster FP, Farzan F, Croarkin PE, Galletly C, Kaess M, Bender S, Koenig J. Transcranial magnetic stimulation in the treatment of adolescent depression: a systematic review and meta-analysis of aggregated and individual-patient data from uncontrolled studies. *Eur Child Adolesc Psychiatry*. 2022 Oct;31(10):1501-1525. doi: [10.1007/s00787-022-02021-7](https://doi.org/10.1007/s00787-022-02021-7). Epub 2022 Jun 24. PMID: 35751003; PMCID: PMC9532325.
23. Tendler, A., Goerigk, S., Zibman, S., Ouaknine, S., Harmelech, T., Pell, G., Zangen, A., Harvey, S., Grammer, G., Stehberg, J., Adefolarin, O., Muir, O., MacMillan, C., Ghelber, D., Duffy, W., Mania, I., Faruqui, Z., Munasifi, F., Antin, T., Padberg, F., Roth, Y. Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis, *Psychiatry Research*, Volume 324, 2023, 115179, ISSN 0165-1781, <https://doi.org/10.1016/j.psychres.2023.115179>. (<https://www.sciencedirect.com/science/article/pii/S0165178123001300>)
24. Walter, H. J., Abright, A. R., Bukstein, O. G., Diamond, J., Keable, H., Ripperger-Suhler, J., & Rockhill, C. (2023). Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. *Journal of the American Academy of Child & Adolescent Psychiatry*, 62(5), 479-502. <https://doi.org/10.1016/j.jaac.2022.10.001>
25. Wada, M., Nakajima, S., Taniguchi, K., Honda, S., Mimura, Y., Takemura, R., ... & Noda, Y. (2025). Effectiveness of sequential bilateral repetitive transcranial stimulation versus bilateral theta burst stimulation for patients with treatment-

resistant depression (BEAT-D): A randomized non-inferiority clinical trial. Brain Stimulation, 18(1), 25-33.

<https://www.sciencedirect.com/science/article/pii/S1935861X24016735>

Related Documents

GUIDES / HANDOUTS

None

FORMS

[Transcranial Magnetic Stimulation \(TMS\) Request Form](#)

Document History

Date	Action	By Whom	Summary
09/2025	Revision	Medical Policy Workgroup	• Clarified language regarding ECT recommendations. • Add child and adolescent indication from the FDA. • 10 references removed. • 3 references added. • Updated the summary of evidence.
02/2025	New	Dr. J. Langlow	Florida Blue requires age to start at 15 years old.

Disclosure: Lucet reserves the right to change and modify this document at any time and to provide notice to all affected parties in a reasonable and acceptable timeframe and format.